[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-433480-105":59,"doc-detail-433480-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","arginine-vasopressin-avp-deficiency-diagnosis-and-treatment-an-update","Arginine Vasopressin (AVP) Deficiency - Diagnosis and Treatment - An Update","","The hypothalamo-neurohypophysial axis transports arginine vasopressin (AVP) and oxytocin (OXT) from magnocellular neurons to the posterior pituitary for systemic release. AVP is the central endocrine regulator of water balance, while OXT supports parturition, lactation, and socio-emotional processing. AVP deficiency (AVP-D) reflects hypothalamic-posterior pituitary injury and presents with hypotonic polyuria and polydipsia, with dehydration vulnerability. Diagnosis distinguishes AVP-D from AVP resistance and primary polydipsia using copeptin-based stimulation, while treatment relies on individualized desmopressin plus education to prevent hypernatremia and hyponatremia. OXT deficiency is emerging, but validated diagnostics and definitive therapies remain limited.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/arginine-vasopressin-avp-deficiency-diagnosis-and-treatment-an-update/433480/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/arginine-vasopressin-avp-deficiency-diagnosis-and-treatment-an-update/433480.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"How is arginine vasopressin deficiency (AVP-D) defined clinically?","Question",{"text":113,"@type":114},"AVP-D belongs to the polyuria–polydipsia syndrome characterized by hypotonic polyuria (>40–50 mL/kg/24 h) together with fluid intake >3 L/day, after osmotic diuresis is excluded.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why is it important to differentiate AVP-D from AVP resistance and primary polydipsia?",{"text":118,"@type":114},"Therapeutic approaches differ across these conditions, and inappropriate treatment may be harmful, so accurate classification is critical for patient safety.",{"name":120,"@type":111,"acceptedAnswer":121},"What diagnostic strategies have improved identification of AVP secretion problems?",{"text":122,"@type":114},"Copeptin measurement after hypertonic saline infusion provides excellent diagnostic accuracy, while arginine stimulation is a better-tolerated alternative with lower diagnostic performance.",{"name":124,"@type":111,"acceptedAnswer":125},"How is AVP deficiency typically treated, and what key safety concerns must be managed?",{"text":126,"@type":114},"Treatment relies on individualized desmopressin replacement once or several times daily, with ongoing vigilance for dilutional hyponatremia and continued psychological symptoms despite adequate therapy.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},433480,1791160115,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":4},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| Review Article |\n| --- |\n|  |\n\nArginine Vasopressin (AVP) Deficiency: Diagnosis and  \nTreatment – An Update  \nMirjam Christ‑Crain1,2  \nDepartments of 1Endocrinology, Diabetology and Metabolism, 2Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland  \nAbstract  \nThe hypothalamo‑neurohypophysial axis comprises magnocellular neurons in the supraoptic and paraventricular nuclei that traffic arginine vasopressin (AVP) and oxytocin (OXT) to the posterior pituitary for systemic release. AVP is the key endocrine determinant of water balance whereas OXT orchestrates parturition and lactation and shapes socio‑emotional processing. AVP‑D results from hypothalamic‑posterior pituitary injury and presents with hypotonic polyuria, polydipsia, and vulnerability to dehydration when access to water is limited. The diagnostic task is to separate AVP‑D fromAVP‑R and primary polydipsia. Copeptin‑based stimulation tests have transformed this work‑up by providing accurate readouts ofAVP secretion. Treatment relies on individualized desmopressin with patient education to prevent hypernatremia and desmopressin‑associated hyponatremia. OXT deficiency is only now entering clinical focus. It likely accompanies AVP‑D in lesions affecting the hypothalamus/posterior pituitary and may contribute to social dysfunction, anxiety, and reduced quality of life; however, validated diagnostic tools and definitive therapeutic data are still lacking.  \nKeywords: AVP deficiency, oxytocin, sodium  \nIntroductIon  \nArginine vasopressin deficiency (AVP‑D) belongs to the polyuria–polydipsia syndrome, defined by hypotonic polyuria (>40–50 mL/kg body weight per 24 hour) together with fluid intake >3 L/day.[1] Once osmotic diuresis has been excluded, the key diagnostic step is to differentiate AVP‑D from AVP resistance (AVP‑R) and from primary polydipsia. The updated terms AVP‑D andAVP‑R have been adopted to avoid confusion with diabetes mellitus and to enhance patient safety.[2]  \nAccurate classification of polyuria‑polydipsia syndromes is crucial, since therapeutic approaches differ and inappropriate treatment may be detrimental. Over the past decade, diagnostic testing has advanced through the use of copeptin mirroring AVP secretion.[3] Copeptin measurement following hypertonic saline infusion provides excellent diagnostic accuracy, but requires close sodium monitoring and continuous supervision. [4] Arginine stimulation has emerged as abetter‑tolerated alternative, however with a lower diagnostic performance.[4] A recent head‑to‑head comparison of these protocols provided further guidance on their relative strengthsand limitations.  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code:\u003Cbr>| Website:\u003Cbr>[https://journals.lww.com/indjem/](https://journals.lww.com/indjem/) |\n|  | DOI:\u003Cbr>10.4103/ijem.ijem_995_25 |\n\nTreatment of AVP deficiency is generally straightforward and relies on individualized desmopressin replacement administered once or several times daily.[1] Nonetheless, clinicians must remain vigilant for dilutional hyponatremia. Moreover, patients frequently continue to experience psychological symptoms even under adequate desmopressin therapy. Given the close anatomical relationship between vasopressinergic and oxytocinergic neurons, hypothalamic‑pituitary lesions causing AVP deficiency may also impair oxytocin secretion. The diagnosis of oxytocin deficiency remains elusive, as baseline concentrations are uninformative.  \n3,4‑methylenedioxymethamphetamine (MDMA) has provided first experimental insights into this entity.[5]  \nThis review discusses the rationale for the nomenclature change and summarizes recent progress in diagnostic approaches. In  \nAddress for correspondence: Prof. Mirjam Christ‑Crain, Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel 4031, Switzerland.  \nE‑mail: mirjam.christ‑[crain@usb.ch](crain@usb.ch)  \nSubmitted: 17‑Nov‑2025  \nAccepted: 03‑Dec‑2025  \nRe","cbCaiuo9oVeD1GyY","https://ap.wps.com/l/cbCaiuo9oVeD1GyY","pdf",803357,"English","# Introduction\n## Nomenclature update and diagnostic rationale\n# Diagnostic approaches\n## Copeptin-based stimulation tests\n## Arginine stimulation alternatives\n# Treatment of AVP deficiency\n## Desmopressin replacement and monitoring\n# Oxytocin deficiency and emerging perspectives\n## Diagnostic limitations and experimental insights\n# Practical considerations and outlook","[{\"question\":\"How is arginine vasopressin deficiency (AVP-D) defined clinically?\",\"answer\":\"AVP-D belongs to the polyuria–polydipsia syndrome characterized by hypotonic polyuria (\\u003e40–50 mL/kg/24 h) together with fluid intake \\u003e3 L/day, after osmotic diuresis is excluded.\"},{\"question\":\"Why is it important to differentiate AVP-D from AVP resistance and primary polydipsia?\",\"answer\":\"Therapeutic approaches differ across these conditions, and inappropriate treatment may be harmful, so accurate classification is critical for patient safety.\"},{\"question\":\"What diagnostic strategies have improved identification of AVP secretion problems?\",\"answer\":\"Copeptin measurement after hypertonic saline infusion provides excellent diagnostic accuracy, while arginine stimulation is a better-tolerated alternative with lower diagnostic performance.\"},{\"question\":\"How is AVP deficiency typically treated, and what key safety concerns must be managed?\",\"answer\":\"Treatment relies on individualized desmopressin replacement once or several times daily, with ongoing vigilance for dilutional hyponatremia and continued psychological symptoms despite adequate therapy.\"}]","Arginine Vasopressin (AVP) Deficiency - Diagnosis and Treatment - An Update | PDF",1790664247,18]